NDAORALTABLET
Approved
Jul 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
BRILINTA (ticagrelor) by AstraZeneca is p2y12 receptor antagonists [moa]. Approved for acute coronary syndrome, coronary artery disease, myocardial infarction and 1 more indications. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRILINTA (ticagrelor) is an oral P2Y12 platelet inhibitor approved by the FDA in July 2011 for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS), established coronary artery disease (CAD), or recent myocardial infarction. It works by irreversibly blocking the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation. The drug is positioned as a key antiplatelet therapy for secondary prevention in high-risk cardiovascular and cerebrovascular patients, often used in combination with aspirin.
$0.7BPart D
10.2 years to LOEMechanism of Action
P2Y12 Receptor Antagonists
Pharmacologic Class:
P2Y12 Platelet Inhibitor
Indications (4)
Worked on BRILINTA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.